Floatz logo

HUMAN INTERLEUKIN 2 (IL2, T-CELL GROWTH FACTOR, TCGF) (2-133) VARIANT (A1 DELETED, PRO65>LYS, CYS125>SER), NON-GLYCOSYLATED, PRODUCED IN ESCHERICHIA COLI, CONJUGATED AT N6 OF K65 WITH A PEG DERIVATIVE (30KDA)

Hepatocellular Carcinoma

Sanofiprotein_peptidePhase 2Active
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
65/ 100

Competitive context

520 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

HUMAN INTERLEUKIN 2 (IL2, T-CELL GROWTH FACTOR, TCGF) (2-133) VARIANT (A1 DELETED, PRO65>LYS, CYS125>SER), NON-GLYCOSYLATED, PRODUCED IN ESCHERICHIA COLI, CONJUGATED AT N6 OF K65 WITH A PEG DERIVATIVE (30KDA) is also rated in:

esophageal squamous cell carcinomaDormant
C
Indicative ·
33 / 100
View asset →
gastric cancerDormant
C
Indicative ·
33 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →